IL-6 was essential for MAPK activation; even with oncogenic KRAS mutations, the absence of IL-6 halted cancer development in PDAC mouse models [219] and was shown to prevent initiation while enhancing the progression of lung cancer driven by KRAS mutations [220]. Here, KRAS is linked to lung carcinoma.